THYSSENKRUPP NUCERA AG & CO (NCH2.DE) Fundamental Analysis & Valuation

FRA:NCH2 • DE000NCA0001

Current stock price

8.125 EUR
+0.05 (+0.62%)
Last:

This NCH2.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NCH2.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NCH2 has reported negative net income.
  • NCH2 had a positive operating cash flow in the past year.
  • In the past 5 years NCH2 has always been profitable.
  • In multiple years NCH2 reported negative operating cash flow during the last 5 years.
NCH2.DE Yearly Net Income VS EBIT VS OCF VS FCFNCH2.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • NCH2 has a Return On Assets of -0.65%. This is amonst the worse of the industry: NCH2 underperforms 84.78% of its industry peers.
  • NCH2 has a worse Return On Equity (-0.99%) than 84.78% of its industry peers.
Industry RankSector Rank
ROA -0.65%
ROE -0.99%
ROIC N/A
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
NCH2.DE Yearly ROA, ROE, ROICNCH2.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 2 4 6 8 10

1.3 Margins

  • In the last couple of years the Profit Margin of NCH2 has declined.
  • NCH2 has a Gross Margin of 14.56%. This is in the lower half of the industry: NCH2 underperforms 78.26% of its industry peers.
  • NCH2's Gross Margin has declined in the last couple of years.
  • NCH2 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
NCH2.DE Yearly Profit, Operating, Gross MarginsNCH2.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NCH2.DE Health Analysis

2.1 Basic Checks

  • NCH2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NCH2 remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for NCH2 remains at a similar level compared to 5 years ago.
  • NCH2 has a worse debt/assets ratio than last year.
NCH2.DE Yearly Shares OutstandingNCH2.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NCH2.DE Yearly Total Debt VS Total AssetsNCH2.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • NCH2 has an Altman-Z score of 3.03. This indicates that NCH2 is financially healthy and has little risk of bankruptcy at the moment.
  • NCH2's Altman-Z score of 3.03 is amongst the best of the industry. NCH2 outperforms 84.78% of its industry peers.
  • NCH2 has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • NCH2 has a Debt to Equity ratio of 0.03. This is amongst the best in the industry. NCH2 outperforms 97.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.03
ROIC/WACCN/A
WACC7.4%
NCH2.DE Yearly LT Debt VS Equity VS FCFNCH2.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • NCH2 has a Current Ratio of 2.80. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.
  • NCH2 has a better Current ratio (2.80) than 95.65% of its industry peers.
  • A Quick Ratio of 2.31 indicates that NCH2 has no problem at all paying its short term obligations.
  • The Quick ratio of NCH2 (2.31) is better than 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.31
NCH2.DE Yearly Current Assets VS Current LiabilitesNCH2.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NCH2.DE Growth Analysis

3.1 Past

  • NCH2 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -142.86%.
  • The earnings per share for NCH2 have been decreasing by -26.62% on average. This is quite bad
  • Looking at the last year, NCH2 shows a very negative growth in Revenue. The Revenue has decreased by -20.37% in the last year.
  • The Revenue has been growing by 27.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-142.86%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-128.57%
Revenue 1Y (TTM)-20.37%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-43.89%

3.2 Future

  • Based on estimates for the next years, NCH2 will show a very strong growth in Earnings Per Share. The EPS will grow by 109.64% on average per year.
  • The Revenue is expected to grow by 15.35% on average over the next years. This is quite good.
EPS Next Y70.58%
EPS Next 2Y132.91%
EPS Next 3Y116.24%
EPS Next 5Y109.64%
Revenue Next Year-33.39%
Revenue Next 2Y-9.55%
Revenue Next 3Y-0.45%
Revenue Next 5Y15.35%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NCH2.DE Yearly Revenue VS EstimatesNCH2.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NCH2.DE Yearly EPS VS EstimatesNCH2.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. NCH2.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NCH2. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 49.93, which means the current valuation is very expensive for NCH2.
  • Based on the Price/Forward Earnings ratio, NCH2 is valued a bit more expensive than 78.26% of the companies in the same industry.
  • NCH2's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.19.
Industry RankSector Rank
PE N/A
Fwd PE 49.93
NCH2.DE Price Earnings VS Forward Price EarningsNCH2.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NCH2 is valued more expensive than 80.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 95.78
NCH2.DE Per share dataNCH2.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • NCH2's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NCH2's earnings are expected to grow with 116.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y132.91%
EPS Next 3Y116.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NCH2.DE Dividend Analysis

5.1 Amount

  • NCH2 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NCH2.DE Fundamentals: All Metrics, Ratios and Statistics

THYSSENKRUPP NUCERA AG & CO

FRA:NCH2 (3/30/2026, 5:29:15 PM)

8.125

+0.05 (+0.62%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)02-11
Earnings (Next)05-12
Inst Owners9.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.03B
Revenue(TTM)729.20M
Net Income(TTM)-7.40M
Analysts76.84
Price Target11.11 (36.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-296.08%
Min EPS beat(2)-492.16%
Max EPS beat(2)-100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.68%
Min Revenue beat(2)-12.74%
Max Revenue beat(2)-2.62%
Revenue beat(4)0
Avg Revenue beat(4)-8.39%
Min Revenue beat(4)-12.74%
Max Revenue beat(4)-2.62%
Revenue beat(8)1
Avg Revenue beat(8)-4.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.91%
PT rev (3m)0.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)175.66%
EPS NY rev (3m)4.09%
Revenue NQ rev (1m)-35.71%
Revenue NQ rev (3m)-34.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 49.93
P/S 1.41
P/FCF N/A
P/OCF 63.74
P/B 1.37
P/tB 1.55
EV/EBITDA 95.78
EPS(TTM)-0.06
EYN/A
EPS(NY)0.16
Fwd EY2%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.13
OCFY1.57%
SpS5.77
BVpS5.92
TBVpS5.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.65%
ROE -0.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.56%
FCFM N/A
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 6.58
Cap/Depr 295.49%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion 423.68%
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.31
Altman-Z 3.03
F-Score4
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)192.94%
Cap/Depr(5y)124.39%
Cap/Sales(3y)2.25%
Cap/Sales(5y)1.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-142.86%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-128.57%
EPS Next Y70.58%
EPS Next 2Y132.91%
EPS Next 3Y116.24%
EPS Next 5Y109.64%
Revenue 1Y (TTM)-20.37%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-43.89%
Revenue Next Year-33.39%
Revenue Next 2Y-9.55%
Revenue Next 3Y-0.45%
Revenue Next 5Y15.35%
EBIT growth 1Y-86.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year562.17%
EBIT Next 3Y202.31%
EBIT Next 5Y132.76%
FCF growth 1Y114.4%
FCF growth 3Y-49.91%
FCF growth 5Y34.5%
OCF growth 1Y180.81%
OCF growth 3Y-16.84%
OCF growth 5Y63.58%

THYSSENKRUPP NUCERA AG & CO / NCH2.DE Fundamental Analysis FAQ

What is the fundamental rating for NCH2 stock?

ChartMill assigns a fundamental rating of 4 / 10 to NCH2.DE.


What is the valuation status for NCH2 stock?

ChartMill assigns a valuation rating of 2 / 10 to THYSSENKRUPP NUCERA AG & CO (NCH2.DE). This can be considered as Overvalued.


What is the profitability of NCH2 stock?

THYSSENKRUPP NUCERA AG & CO (NCH2.DE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for THYSSENKRUPP NUCERA AG & CO?

The Earnings per Share (EPS) of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is expected to grow by 70.58% in the next year.